Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
← catalyst calendarNCT05417594 · readout in 537 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
695estimated
Sites
32
Countries
Australia, Germany, South Korea +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-24 | actual | When the study began enrolling |
| Primary completion | 2028-02-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-07 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Malignancies
Interventions
- Drug: AZD9574
- Drug: Temozolomide (TMZ)
- Drug: [11C]AZ1419 3391
- Drug: Trastuzumab Deruxtecan (T-DXd)
- Drug: Datopotamab Deruxtecan (Dato-DXd)
Primary outcomes
what the primary-completion date above is the date OFIncidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)
measured From first dose to post-treatment follow-up (approximately three years)
Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs
measured From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)
measured From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
Incidence of Dose Limiting Toxicities (DLTs)
measured Cycle 0 and Cycle 1 (Day 1 to Day 35)
Publications
- PMID 37967136 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed